Project Grant R01CA290737
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$578K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This $639,004 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Mayo Clinic to evaluate the use of a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The award will fund the collection and analysis of tumor tissue and blood samples to investigate the mechanisms by which NT-I7 can enhance immune response and improve the efficacy of checkpoint inhibitor...
This National Cancer Institute (NCI) Project Grant Award under the Cancer Treatment Research Program (CFDA 93.395) provides $633,355 to Northwestern University to conduct research on sustaining the metabolic fitness of effector CD8+ T cells for enhanced anti-tumor immunity. The research aims to define the metabolic and cellular effects of sustaining the glutathione-glutathione peroxidase 4 (GSH-GPX4) axis while inhibiting the adenosine A2A receptor (A2AR) signaling pathway in effector T...
This federal Project Grant award of $212,567 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) will support a research specialist's roles in the laboratory of Dr. Timothy Chan and the leadership of the Computational Immunogenomics Platform (IGP) at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The funding will enable the specialist to conduct computational analyses of cancer patient genomic data to advance the field of...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is providing $1,876,547.00 to New York University School of Medicine to conduct research aimed at optimizing T cell receptor (TCR)-CD3 signaling for cancer immunotherapy. The project will use in vitro methods, structural analysis, and in vivo testing to identify TCR mutations that can enhance immune-mediated tumor killing without losing antigen specificity. The goal is to...
This federal Project Grant award of $550,255 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will support research to develop a novel "Structural Surfaceomics" technology to systematically identify cancer-specific conformations of surface proteins as potential immunotherapy targets. The project aims to:
Further advance the Structural Surfaceomics technology to uncover conformation-specific cancer antigens across multiple tumor models, with...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $218,375 to Northwestern University to elucidate the mechanism of resistance to immunotherapy in Merkel cell carcinoma (MCC). The award, which runs from July 2024 to January 2026, supports research to spatially and functionally identify the critical receptor-ligand interactions triggering T cell-mediated response to immune checkpoint blockade in MCC. Key objectives include...
This Project Grant award, totaling $639,742, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Northwestern University in Evanston, Illinois. The purpose of the award is to conduct research to "HARNESS ALTERNATIVE SPLICING TO EXPAND THE TUMOR ANTIGEN REPERTOIRE AND BOOST ANTITUMOR IMMUNITY IN GLIOBLASTOMA". The grant will support cutting-edge research at Northwestern University to explore innovative approaches to...
This $216,736 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to Vanderbilt University to develop and test a biomaterial therapy that delivers a RIG-I agonist, 5'-triphosphorylated double-stranded RNA (3PRNA), via a polymeric nanocarrier to activate an immune response in mouse models of glioblastoma (GBM), a highly aggressive form of brain cancer. The goals are to 1) engineer the 3PRNA-loaded nanoparticles and evaluate...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $701,408 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research aimed at elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project involves several ongoing Phase II clinical trials exploring the use of newly...